THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 48 filers reported holding THESEUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,889,496 | -73.2% | 702,415 | -7.2% | 1.25% | -73.0% |
| Q2 2023 | $7,062,894 | +4.5% | 757,009 | -0.6% | 4.63% | -17.9% |
| Q1 2023 | $6,759,971 | +73.1% | 761,258 | -2.9% | 5.64% | +66.9% |
| Q4 2022 | $3,905,107 | +33.4% | 784,158 | +55.3% | 3.38% | +27.9% |
| Q3 2022 | $2,928,000 | +4.9% | 504,862 | 0.0% | 2.64% | +11.1% |
| Q2 2022 | $2,792,000 | -32.1% | 504,862 | +41.5% | 2.38% | -37.7% |
| Q1 2022 | $4,114,000 | -20.7% | 356,827 | -12.8% | 3.82% | -15.7% |
| Q4 2021 | $5,191,000 | – | 409,358 | – | 4.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,585,346 | $31,837,872 | 23.54% |
| Lynx1 Capital Management LP | 761,258 | $6,759,971 | 5.64% |
| Omega Fund Management, LLC | 711,479 | $6,317,934 | 4.12% |
| Orbimed Advisors | 17,233,668 | $153,034,972 | 3.00% |
| Fairmount Funds Management LLC | 1,865,671 | $16,567,158 | 2.85% |
| Nextech Invest Ltd. | 611,310 | $5,428,433 | 2.27% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $19,963,963 | 1.44% |
| VR Adviser, LLC | 770,000 | $6,837,600 | 1.34% |
| Opaleye Management Inc. | 488,100 | $4,334,328 | 1.30% |
| Paradigm Biocapital Advisors LP | 1,505,327 | $13,367,304 | 1.27% |